Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: A randomised controlled trial

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 6, 2000, Pages 759-765

  Hall, D R ^a   Odendaal, H J ^a   Steyn, D W ^a   Smith, M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; METHYLDOPA; NIFEDIPINE; PRAZOSIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FETUS DEATH; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; NIFEDIPINE; PRAZOSIN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; VASODILATOR AGENTS;

EID: 0034022176     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb13337.x     Document Type: Article

References (50)

1. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am J Obstet Gynecol 1990; 163: 460–465.
2. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991–1993. London: HMSO, 1996.
3. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America, and the Caribbean. Br J Obstet Gynaecol 1992; 99: 547–553.
4. Theron GB. Maternal mortality in the Cape Province, 1990–1992. S Afr Med J 1996; 86: 412–418.
5. Prins CA, Theron GB, Steyn DW, Geerts LT, De Jong G. Total perinatally related wastage at Tygerberg Hospital: a comparison between 1986 and 1993. S Afr Med J 1997; 87: 808–814.
6. Odendaal ES, Steyn DW, Odendaal HJ. Obstetric causes for delivery of very low birth weight babies at Tygerberg Hospital. Seventeenth Conference on Priorities in Perinatal Care in Southern Africa, March 1998.
7. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med 1995; 23: 1392–1400.
8. Redman CW. Controlled trials of anti-hypertensive drugs in pregnancy. Am J Kidney Dis 1991; 171: 149–153.
9. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28–34 weeks gestation: a randomised controlled trial. Obstet Gynecol 1990; 76: 1070–1075.
10. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 week's gestation: a randomised controlled trial. Am J Obstet Gynecol 1994; 171: 818–822.
11. Derham RJ, Hawkins DF, De Vries LS, Aber VR, Elder MG. Outcome of pregnancies complicated by severe hypertension and delivered before 34 weeks; stepwise logistic regression analysis of prognostic factors. Br J Obstet Gynaecol 1989; 96: 1173–1181.
12. Greer IA, Walker JJ, Bjornsson S, Calder AA. Second line therapy with nifedipine in severe pregnancy induced hypertension. Clin Exper Hyper Preg 1989; B8: 277–292.
13. Odendaal HJ, Steyn DW, Norman K, Kirsten GF, Smith J, Theron GB. Improved perinatal mortality rates in 1001 patients with severe preeclampsia. S Afr Med J 1995; 85: 1071–1076.
14. Hall DR, Odendaal HJ. The addition of a diuretic to anti-hypertensive therapy for early severe hypertension in pregnancy. Int J Gynecol Obstet 1998; 60: 63–64.
15. Barron WM. Hypertension. In: Barron WM, Lindheimer MD, editors. Medical Disorders During Pregnancy. St. Louis, Missouri, USA: Mosby, 1995: 1–36.
16. Redman CW, Beilin LJ, Bonnar J, Ounsted MK. Fetal outcome in trial of anti-hypertensive treatment in pregnancy. Lancet 1976; 2: 753–756.
17. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1: 647–649.
18. Kyle PM, Redman CW. Comparative risk/benefit assessment of drugs used in the management of hypertension in pregnancy. Drug Safety 1992; 7: 223–234.
19. Rubin PC, Butters L, McCabe R. Nifedipine and platelets in pregnancy. Am J Hypertens 1988; 1: 175–177.
20. Tranquilli AL, Garzetti GG, De Tommaso G et al. Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal. Am J Obstet Gynecol 1992; 167: 942–945.
21. Ismail AA, Medhat I, Tawfic TA, Kholeif A. Evaluation of calciumantagonist (nifedipine) in the treatment of pre-eclampsia. Int J Gynecol Obstet 1993; 40: 39–43.
22. Harake B, Gilbert RD, Ashwal S, Power GG. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol 1987; 157: 1003–1008.
23. Blea CW, Barnard JM, Magness RR, Phernetton TM, Hendricks SK. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol 1997; 176: 922–930.
24. Moretti MM, Fairlie FM, Akl S, Khoury AD, Sibai BM. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol 1990; 163: 1844–1848.
25. McEvoy GK, Litvak K, Welsh OH. American Hospital Formulary Service. Bethesda, Maryland, USA: American Society of Health System Pharmacists Inc, 1995.
26. Collins RC, Wallenberg HC. Hypertension in pregnancy. In: Enkin M, Keirse MJ, Renfrew M, Neilson J, editors. A Guide to Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1995: 90–100.
27. Davey DA, MacGillivray I. The classification definition of hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892–898.
28. Theron GB, Thompson ML. A centile chart for birth weight for an urban population of the Western Cape. S Afr Med J 1995; 85: 1289–1292.
29. Vincent J, Meredith PA, Reid JL, Elliot HL, Rubin PC. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 1985; 10: 144–154.
30. Guyatt GH. The treatment of heart failure. A methodological review of the literature. Drugs 1986; 32: 538–568.
31. Bawaskar HS, Bawaskar PH. Management of the cardiovascular manifestations of poisoning by the Indian red scorpion (Mesobuthus tamulus). Br Heart J 1992; 68: 478–480.
32. Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM. A randomised prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992; 167: 879–884.
33. Rao GH, Rao AT. Pharmacology of platelet activation-inhibitory drugs. Indian J Physiol Pharmacol 1994; 38: 69–84.
34. Barton JR, Hiett AK, Conover WB. The use of nifedipine during the postpartum period in patients with severe preeclampsia. Am J Obstet Gynecol 1990; 162: 788–792.
35. Fenakel J, Fenakel G, Appleman ZV, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991; 77: 331–337.
36. Redman C. Hypertension in pregnancy. In: De Swiet M, editor. Medical Disorders in Obstetric Practice. Oxford: Blackwell Science, 1996: 182–225.
37. Moodley J, Moodley VV. Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large, randomised trial. Hypertens Pregnancy 1994; 13: 245–252.
38. Odendaal HJ, Pattinson RC, Du Toit R. Fetal and neonatal outcome in patients with severe pre-eclampsia before 34 weeks. S Afr Med J 1987; 71: 555–558.
39. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257–265.
40. Lubbe WF, Hodge JV. Combined α- and β-adrenoceptor antagonism with prazosin and oxprenolol in control of severe hypertension in pregnancy. N Z Med J 1981; 94: 169–172.
41. Bourget P, Fernandez H, Edouard D et al. Disposition of a new rate controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Eur J Drug Metab Pharmacokinet 1995; 20: 233–241.
42. Norman K, Geerts L, Smith M, Odendaal H, Van Zyl J. Clinical management of the fetus with ARED umbilical artery Doppler flow: a five year prospective study [abstract]. Eleventh Congress of the International Perinatal Doppler Society, Innsbruck, Austria, July 1998.
43. Lindow SW, Daives N, Davey DA, Smith JA. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynaecol 1988; 95: 1276–1281.
44. Puzey MS, Ackovic KL, Lindow SW, Gonin R. The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension. S Afr Med J 1991; 79: 192–194.
45. Allen J, Andersson KE, Forman A et al. Effects of nifedipine on isolated arteries and placental perfusion in the human uteroplacental unit. Clin Exper Hyper Preg 1991; B10: 353–369.
46. Benedetto C, Zonca M, Giarola M, Maula V, Chiarolini L, Carandente F. 24-hour blood pressure monitoring to evaluate the effects of nifedipine in pre- eclampsia and in chronic hypertension in pregnancy. Br J Obstet Gynaecol 1997; 104: 682–688.
47. Davis WB, Wells SR, Kuller JA, Thorp JM. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet Gynecol Surv 1997; 52: 198–201.
48. Laporte J, Ibanez L, Ballarin E, Perez E, Vidal X. Fatal aplastic anaemia associated with nifedipine. Lancet 1998; 352: 619–620.
49. Dommisse J, Davey DA, Roos PJ. Prazosin and oxprenalol therapy in hypertension. S Afr Med J 1983; 64: 231–233.
50. Rubin PC, Butters L, Low RA, Reid JL. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Br J Clin Pharmac 1983; 16: 543–547.